For active psoriatic arthritis (PsA) in adult TNFi-IR patients1

Powerful disease
control2,3

RINVOQ achieved its ranked secondary endpoint of Minimal Disease Activity at Week 24, with response rates up to ~1 year2,3

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor

RINVOQ achieved its ranked secondary endpoint of Minimal Disease Activity at Week 24, with response rates up to ~1 year2,3

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor

Clinical Trial Overview

Clinical Trial Overview

SELECT-PsA 2 Clinical Trial Overview

*P<0.001 RINVOQ vs placebo3

SELECT-PsA 2 Study Design Intro:1

24-week, double-blind, placebo-controlled study of 642 adult patients with moderately to severely active PsA who had an inadequate response or intolerance to at least one biologic DMARD. Patients were randomized to receive upadacitinib or placebo. The primary endpoint was proportion of patients achieving ACR20 response at Week 12 vs placebo.

See Study Details

ACR=American College of Rheumatology; ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 of the 5 other core criteria, including patient and physician global assessments, health assessment questionnaire — disability index (HAQ‑DI), pain assessment, and high‑sensitivity C‑reactive protein (hs‑CRP); bDMARD=biologic disease‑modifying antirheumatic drug; DMARD=disease‑modifying antirheumatic drug; IR=intolerance or inadequate response; NRI=non‑responder imputation; PsA=psoriatic arthritis; QD=once per day; TNFi=tumor necrosis factor inhibitor

RINVOQ Reels: Your peers discuss clinical data

Dr. Tate and Dr. Siegel discuss RINVOQ's joint and skin efficacy data
in treating patients with active PsA

"RINVOQ hits the mark for many of the considerations for PsA patients"
- Dr Rachel Tate, DO, RhMSUS, FACR

Transcript

Meet the Key Opinion Leaders

Dr. Rachel Tate, DO, RhMSUS, FACR received her osteopathic medical degree from Des Moines University and completed her internal medicine residency at Plaza Medical Center of Fort Worth. She completed her rheumatology and musculoskeletal ultrasound fellowships at Franciscan Health Alliance in Chicago. Dr. Tate is a clinical rheumatologist at South Florida Rheumatology.

Dr. Evan Siegel, MD, FACP, FACR completed his Fellowship at the New York University Medical Center Hospital for Joint Disease. He serves as the assistant Clinical Professor of Medicine at Georgetown University School of Medicine, as well as the Medical Director of Arthritis and Rehabilitation Therapy Services, the physical therapy division of Arthritis and Rheumatism Associates, P.C.

Minimal disease activity ACHIEVED
AT WEEK 24 WITH RESPONSE RATES
at WEEK 562,3

Minimal Disease Activity (MDA) is achieved when meeting 5 of 7 criteria:4

  • Tender joint count ≤1
  • Swollen joint count ≤1
  • PASI ≤1 or BSA-Psoriasis ≤3%
  • Pain ≤1.5 (0—10 NRS)
  • Patient Global Assessment-Disease Activity ≤2 (0—10 NRS)
  • HAQ-DI ≤0.5
  • LEI ≤1

Get a summary of
the MDA data

Download RINVOQ MDA Flashcard

SELECT-PsA 2 (biologic DMARD-IR): MDA over time2,3

RINVOQ is indicated for TNFi-IR patients

SELECT-PsA 2 (biologic DMARD-IR): MDA over time2,3

RINVOQ is indicated for TNFi-IR patients

SELECT-PsA 1: MDA over time SELECT-PsA 1: MDA over time SELECT-PsA 1: MDA over time

~25% of RINVOQ patients achieved MDA at Week 24 vs 3% with placebo3,*

Nearly 30% of RINVOQ patients achieved MDA at ~1 year2

Data LIMITATIONS: Data labeled as a ranked secondary endpoint were multiplicity controlled for comparisons. All other comparisons were not adjusted for multiplicity; therefore, statistical significance has not been established.

~25% of RINVOQ patients achieved MDA at Week 24 vs 3% with placebo3,*

Nearly 30% of RINVOQ patients achieved MDA at ~1 year2

See Study Details
See Baseline Characteristics
See Footnotes and Definitions
Register Today

RINVOQ SAFETY DATA

Review the safety profile of RINVOQ,
including both short- and long-term analyses

SEE SAFETY PROFILE